Ophthalmology company Nicox SA (Euronext Growth Paris:ALCOX) on Monday announced an exclusive research and licence option agreement with Glaukos Corporation (NYSE:GKOS), US ophthalmic pharmaceutical and medical device company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
Under the agreement, Glaukos will fund and conduct preclinical research on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor. This programme will explore indications for the treatment of glaucoma, including neuroprotection, and the treatment of retinal diseases.
Glaukos has an option to license NCX 1728 on an exclusive global basis for development in glaucoma and retinal diseases. The agreement includes standard economic provisions for a licence agreement of this nature, Nicox said.
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study
Nicox and Glaukos sign exclusive research and licensing option agreement
Creo Medical forms strategic partnership with Micro-Tech via EUR36.7m subsidiary sale
Epitomee Medical's Capsule cleared by FDA for weight management
Eurofins strengthens biopharma testing in US with Infinity Labs acquisition